Cipla arm, Alvotech enter partnership for commercialization of adalimumab biosimilar AVT02

Written by Medical Dialogues Bureau Published On 2019-07-29T09:45:06+05:30 | Updated On 29 July 2019 9:45 AM IST

Cipla arm, Alvotech enter partnership for commercialization of adalimumab biosimilar AVT02

Under the partnership, Alvotech will be responsible for the development and supply of AVT02, an adalimumab biosimilar, while Cipla Gulf will be responsible for registration and commercialization.

Mumbai: Biopharmaceutical company Alvotech and Cipla Gulf FZ LLC ("Cipla Gulf"), a wholly-owned subsidiary of the global pharmaceutical company Cipla Limited, recently announced that Alvotech and Cipla Gulf have entered into an exclusive partnership for the commercialization of AVT02, an adalimumab biosimilar, in select emerging markets.

Under the partnership, Alvotech will be responsible for the development and supply of the product, while Cipla Gulf will be responsible for registration and commercialization. Alvotech's AVT02 is in Phase-3 clinical development ahead of filing with the European Medicines Agency (EMA) and the United States Food and Drug Administration (USFDA) by early 2020.

AVT02 is a mAb biosimilar to AbbVie's HUMIRA, which is a leading drug indicated for the treatment of several autoimmune diseases, including (but not limited to) Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Plaque Psoriasis (PP), Psoriatic Arthritis, Ulcerative Colitis (UC), and Crohn's Disease (CD). It neutralizes the Tumor Necrosis Alpha (TNF-α) involved in systemic inflammation and the above-mentioned diseases. AbbVie's HUMIRA recorded sales of about US$20 billion in 2018, making it the largest-selling blockbuster medicine worldwide.

Commenting on the partnership, Robert Wessman, Alvotech's founder and Chairman said, "We are very proud to announce our strategic alliance with Cipla, a leading global company with over 84 years of history. By partnering with Cipla, Alvotech gains access to Cipla's strong commercial network in select emerging markets and deep market experience, which will ultimately benefit patients who will get better access to high-quality biosimilars."

Nishant Saxena, CEO, International Business (Europe & Emerging Markets), Cipla, said, "This is a significant addition to our portfolio of offerings in the global biosimilars space which includes trastuzumab, bevacizumab, etanercept and pegfilgrastim. Adalimumab is the highest-selling pharmaceutical product in the world and the preferred anti-inflammatory treatment option for several autoimmune diseases.

"We look forward to partnering with Alvotech and leveraging our own strong commercial strengths and capabilities to make this highly effective treatment option available to patients in several countries, "Saxena added.

Alvotechankylosing spondylitisanti-inflammatory treatmentautoimmune diseasesAVT02biopharmaceuticalbiosimilarCiplaCipla GulfCipla partnershipCrohn diseaseGlobal Pharmaceutical Companypharmapharma companypharma newsplaque psoriasispsoriatic arthritisrheumatoid arthritisTumor Necrosis Alphaulcerative colitisUSFDA

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Medical Dialogues Bureau

Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here